Healthcare delivery

Injectable drugs and in-patient care drive the highest of cost for employers.

Megan Cook left a traditional brokerage to launch her own firm targeted at changing the way employers approach medical benefits.

The final ruling includes protections intended to remedy historical challenges with AHPs and to prevent AHPs from discriminating against individuals based on health reasons.

The online retail giant’s purchase of the e-pharmacy may deliver convenience but who will monitor customers for side effects and wrong dosages?

In the first 10 days of July, at least ten drugmakers and biotechnology companies have raised prices on at least 20 brand-name medicines.

In an effort to bring insurance carriers back to ACA exchanges, the U.S. government is increasing funding to insurers, which could spur brokers to recommend the exchanges to clients.

As the new head of Amazon, Berkshire and JPMorgan’s healthcare venture gets down to work, we can see what his plans might be for the future of large employer health plans.

The online retail conglomerate takes another step into the health market with its announcement to buy PillPack, surprising several industry leaders.

The online retail conglomerate takes another step into the healthcare market with its announcement to buy online pharmacy, surprising several industry leaders.

Employers have an opportunity to help employees make better decisions about retirement savings to address out-of-control medical costs.

The DOL upended the traditional dynamic of company-sponsored benefits and threw a lifeline to millions of small companies and their HR teams.

Employers have an opportunity to help employees make better decisions about retirement savings to address out-of-control medical costs.

The DOL upended the traditional dynamic of company-sponsored benefits and threw a lifeline to millions of small companies and their HR teams.

Attempting to circumvent the costly specialty drug chain, brokers are encouraging clients to shop for FDA-approved drugs outside the U.S.

The health venture established will take aim at intermediaries in the healthcare system as a part of a broad effort to reduce wasteful spending

The world’s biggest pharmaceutical companies, looking to sell a new type of cancer drug that could transform treatment, are grappling with an unusual challenge: finding patients.

The CEO of the Amazon-JPMC-Berkshire Hathaway aims to address the “tapeworm” eating the U.S. economy.

Atul Gawande receives high praise from industry professionals; however determining who will support his plans remains a mystery.

86% indicate they have not yet invested in capabilities to verify data that feeds into their systems.